A year in pharma and biotech R&D: Glimmers of hope in Phase III
This article was originally published in Scrip
At last, some signs that the pharma industry is addressing attrition in the late-stage pipeline – with the biggest annual rise in Phase III products on record.
You may also be interested in...
Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.
GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.
A decade ago, the publication of the human genome foreshadowed an explosion in new drug targets. Those predictions now seem to have been overly optimistic.